Overview of the current status of familial
hypercholesterolaemia care in over 60 countries - The EAS
Familial Hypercholesterolaemia Studies Collaboration (FHSC)

J 2018

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

VALLEJO-VAZ, A.J., M. DE MARCO, C.A.T. STEVENS, A. AKRAM, Tomáš FREIBERGER et. al.

Základní údaje

Originální název

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Autoři

VALLEJO-VAZ, A.J. (826 Velká Británie a Severní Irsko), M. DE MARCO (826 Velká Británie a Severní Irsko), C.A.T. STEVENS (826 Velká Británie a Severní Irsko), A. AKRAM (404 Keňa), Tomáš FREIBERGER (203 Česká republika, garant, domácí), G.K. HOVINGH (528 Nizozemské království), J.J.P. KASTELEIN (724 Španělsko), P. MATA (710 Jižní Afrika), F.J. RAAL (76 Brazílie), R.D. SANTOS (36 Austrálie), H. SORAN (826 Velká Británie a Severní Irsko), G.F. WATTS (36 Austrálie), M. ABIFADEL (422 Libanon), C.A. AGUILAR-SALINAS (484 Mexiko), M. AL-KHNIFSAWI (368 Irák), F.A. ALKINDI (634 Katar), F. ALNOURI (682 Saúdská Arábie), R. ALONSO (152 Chile), K. AL-RASADI (512 Omán), A. AL-SARRAF (414 Kuvajt), T.F. ASHAVAID (356 Indie), C.J. BINDER (40 Rakousko), M.P. BOGSRUD (578 Norsko), M. BOURBON (620 Portugalsko), E. BRUCKERT (250 Francie), K. CHLEBUS (616 Polsko), P. CORRAL (32 Argentina), O. DESCAMPS (56 Belgie), R. DURST (376 Izrael), M. EZHOV (643 Rusko), Z. FRAS (705 Slovinsko), J. GENEST (124 Kanada), U. GROSELJ (705 Slovinsko), M. HARADA-SHIBA (392 Japonsko), M. KAYIKCIOGLU (792 Turecko), K. LALIC (688 Srbsko), C.S.P. LAM (702 Singapur), G. LATKOVSKIS (440 Litva), U. LAUFS (276 Německo), E. LIBEROPOULOS (300 Řecko), J. LIN (156 Čína), V. MAHER (372 Irsko), N. MAJANO (484 Mexiko), A.D. MARAIS (710 Jižní Afrika), W. MARZ (276 Německo), E. MIRRAKHIMOV (40 Rakousko), A.R. MISEREZ (276 Německo), O. MITCHENKO (417 Kyrgyzstán), H.M. NAWAWI (756 Švýcarsko), B.G. NORDESTGAARD (208 Dánsko), G. PARAGH (348 Maďarsko), Z. PETRULIONIENE (440 Litva), B. POJSKIC (70 Bosna a Hercegovina), A. POSTADZHIYAN (100 Bulharsko), A. REDA (818 Egypt), Z. REINER (191 Chorvatsko), W.E. SADOH (566 Nigérie), A. SAHEBKAR (364 Írán), A. SHEHAB (784 Spojené arabské emiráty), A.B. SHEK (860 Uzbekistán), M. STOLL (858 Uruguay), T.C. SU (158 Tchaj-wan), T. SUBRAMANIAM (702 Singapur), A.V. SUSEKOV (643 Rusko), P. SYMEONIDES (196 Kypr), M. TILNEY (470 Malta), B. TOMLINSON (344 Hongkong), T.H. TRUONG (704 Vietnam), A.D. TSELEPIS (300 Řecko), A. TYBJAERG-HANSENB (208 Dánsko), A. VAZQUEZ-CARDENAS (484 Mexiko), M. VIIGIMAA (233 Estonsko), B. VOHNOUT (703 Slovensko), E. WIDEN (246 Finsko), S. YAMASHITA (392 Japonsko), M. BANACH (616 Polsko), D. GAITA (642 Rumunsko), L.X. JIANG (156 Čína), L. NILSSON (752 Švédsko), L.E. SANTOS (608 Filipíny), H. SCHUNKERT (276 Německo), L. TOKGOZOGLU (792 Turecko), J. CAR (826 Velká Británie a Severní Irsko), A.L. CATAPANO (702 Singapur) a K.K. RAY (380 Itálie)

Vydání

Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2018, 0021-9150

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.255

Kód RIV

RIV/00216224:14740/18:00106253

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1016/j.atherosclerosis.2018.08.051

UT WoS

000445908000037

Klíčová slova anglicky

Familial hypercholesterolaemia; Primary dyslipidaemia; FHSC

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 3. 2019 11:31, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in similar to 2/3 countries. Lipoprotein-apheresis is offered in similar to 60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.

Citovat

VALLEJO-VAZ, A.J., M. DE MARCO, C.A.T. STEVENS, A. AKRAM, Tomáš FREIBERGER, G.K. HOVINGH, J.J.P. KASTELEIN, P. MATA, F.J. RAAL, R.D. SANTOS, H. SORAN, G.F. WATTS, M. ABIFADEL, C.A. AGUILAR-SALINAS, M. AL-KHNIFSAWI, F.A. ALKINDI, F. ALNOURI, R. ALONSO, K. AL-RASADI, A. AL-SARRAF, T.F. ASHAVAID, C.J. BINDER, M.P. BOGSRUD, M. BOURBON, E. BRUCKERT, K. CHLEBUS, P. CORRAL, O. DESCAMPS, R. DURST, M. EZHOV, Z. FRAS, J. GENEST, U. GROSELJ, M. HARADA-SHIBA, M. KAYIKCIOGLU, K. LALIC, C.S.P. LAM, G. LATKOVSKIS, U. LAUFS, E. LIBEROPOULOS, J. LIN, V. MAHER, N. MAJANO, A.D. MARAIS, W. MARZ, E. MIRRAKHIMOV, A.R. MISEREZ, O. MITCHENKO, H.M. NAWAWI, B.G. NORDESTGAARD, G. PARAGH, Z. PETRULIONIENE, B. POJSKIC, A. POSTADZHIYAN, A. REDA, Z. REINER, W.E. SADOH, A. SAHEBKAR, A. SHEHAB, A.B. SHEK, M. STOLL, T.C. SU, T. SUBRAMANIAM, A.V. SUSEKOV, P. SYMEONIDES, M. TILNEY, B. TOMLINSON, T.H. TRUONG, A.D. TSELEPIS, A. TYBJAERG-HANSENB, A. VAZQUEZ-CARDENAS, M. VIIGIMAA, B. VOHNOUT, E. WIDEN, S. YAMASHITA, M. BANACH, D. GAITA, L.X. JIANG, L. NILSSON, L.E. SANTOS, H. SCHUNKERT, L. TOKGOZOGLU, J. CAR, A.L. CATAPANO a K.K. RAY. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. Clare: ELSEVIER SCI IRELAND LTD, 2018, roč. 277, OCT, s. 234-255. ISSN 0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2018.08.051.

@article{1498538,
   author = {VallejoandVaz, A.J. and De Marco, M. and Stevens, C.A.T. and Akram, A. and Freiberger, Tomáš and Hovingh, G.K. and Kastelein, J.J.P. and Mata, P. and Raal, F.J. and Santos, R.D. and Soran, H. and Watts, G.F. and Abifadel, M. and AguilarandSalinas, C.A. and AlandKhnifsawi, M. and AlKindi, F.A. and Alnouri, F. and Alonso, R. and AlandRasadi, K. and AlandSarraf, A. and Ashavaid, T.F. and Binder, C.J. and Bogsrud, M.P. and Bourbon, M. and Bruckert, E. and Chlebus, K. and Corral, P. and Descamps, O. and Durst, R. and Ezhov, M. and Fras, Z. and Genest, J. and Groselj, U. and HaradaandShiba, M. and Kayikcioglu, M. and Lalic, K. and Lam, C.S.P. and Latkovskis, G. and Laufs, U. and Liberopoulos, E. and Lin, J. and Maher, V. and Majano, N. and Marais, A.D. and Marz, W. and Mirrakhimov, E. and Miserez, A.R. and Mitchenko, O. and Nawawi, H.M. and Nordestgaard, B.G. and Paragh, G. and Petrulioniene, Z. and Pojskic, B. and Postadzhiyan, A. and Reda, A. and Reiner, Z. and Sadoh, W.E. and Sahebkar, A. and Shehab, A. and Shek, A.B. and Stoll, M. and Su, T.C. and Subramaniam, T. and Susekov, A.V. and Symeonides, P. and Tilney, M. and Tomlinson, B. and Truong, T.H. and Tselepis, A.D. and TybjaergandHansenb, A. and VazquezandCardenas, A. and Viigimaa, M. and Vohnout, B. and Widen, E. and Yamashita, S. and Banach, M. and Gaita, D. and Jiang, L.X. and Nilsson, L. and Santos, L.E. and Schunkert, H. and Tokgozoglu, L. and Car, J. and Catapano, A.L. and Ray, K.K.},
   article_location = {Clare},
   article_number = {OCT},
   doi = {http://dx.doi.org/10.1016/j.atherosclerosis.2018.08.051},
   keywords = {Familial hypercholesterolaemia; Primary dyslipidaemia; FHSC},
   language = {eng},
   issn = {0021-9150},
   journal = {Atherosclerosis},
   title = {Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)},
   url = {https://www.sciencedirect.com/science/article/pii/S0021915018313595?via%3Dihub},
   volume = {277},
   year = {2018}
}

TY  - JOUR
ID  - 1498538
AU  - Vallejo-Vaz, A.J. - De Marco, M. - Stevens, C.A.T. - Akram, A. - Freiberger, Tomáš - Hovingh, G.K. - Kastelein, J.J.P. - Mata, P. - Raal, F.J. - Santos, R.D. - Soran, H. - Watts, G.F. - Abifadel, M. - Aguilar-Salinas, C.A. - Al-Khnifsawi, M. - AlKindi, F.A. - Alnouri, F. - Alonso, R. - Al-Rasadi, K. - Al-Sarraf, A. - Ashavaid, T.F. - Binder, C.J. - Bogsrud, M.P. - Bourbon, M. - Bruckert, E. - Chlebus, K. - Corral, P. - Descamps, O. - Durst, R. - Ezhov, M. - Fras, Z. - Genest, J. - Groselj, U. - Harada-Shiba, M. - Kayikcioglu, M. - Lalic, K. - Lam, C.S.P. - Latkovskis, G. - Laufs, U. - Liberopoulos, E. - Lin, J. - Maher, V. - Majano, N. - Marais, A.D. - Marz, W. - Mirrakhimov, E. - Miserez, A.R. - Mitchenko, O. - Nawawi, H.M. - Nordestgaard, B.G. - Paragh, G. - Petrulioniene, Z. - Pojskic, B. - Postadzhiyan, A. - Reda, A. - Reiner, Z. - Sadoh, W.E. - Sahebkar, A. - Shehab, A. - Shek, A.B. - Stoll, M. - Su, T.C. - Subramaniam, T. - Susekov, A.V. - Symeonides, P. - Tilney, M. - Tomlinson, B. - Truong, T.H. - Tselepis, A.D. - Tybjaerg-Hansenb, A. - Vazquez-Cardenas, A. - Viigimaa, M. - Vohnout, B. - Widen, E. - Yamashita, S. - Banach, M. - Gaita, D. - Jiang, L.X. - Nilsson, L. - Santos, L.E. - Schunkert, H. - Tokgozoglu, L. - Car, J. - Catapano, A.L. - Ray, K.K.
PY  - 2018
TI  - Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
JF  - Atherosclerosis
VL  - 277
IS  - OCT
SP  - 234-255
EP  - 234-255
PB  - ELSEVIER SCI IRELAND LTD
SN  - 00219150
KW  - Familial hypercholesterolaemia
KW  - Primary dyslipidaemia
KW  - FHSC
UR  - https://www.sciencedirect.com/science/article/pii/S0021915018313595?via%3Dihub
N2  - Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in similar to 2/3 countries. Lipoprotein-apheresis is offered in similar to 60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.
ER  -

VALLEJO-VAZ, A.J., M. DE MARCO, C.A.T. STEVENS, A. AKRAM, Tomáš FREIBERGER, G.K. HOVINGH, J.J.P. KASTELEIN, P. MATA, F.J. RAAL, R.D. SANTOS, H. SORAN, G.F. WATTS, M. ABIFADEL, C.A. AGUILAR-SALINAS, M. AL-KHNIFSAWI, F.A. ALKINDI, F. ALNOURI, R. ALONSO, K. AL-RASADI, A. AL-SARRAF, T.F. ASHAVAID, C.J. BINDER, M.P. BOGSRUD, M. BOURBON, E. BRUCKERT, K. CHLEBUS, P. CORRAL, O. DESCAMPS, R. DURST, M. EZHOV, Z. FRAS, J. GENEST, U. GROSELJ, M. HARADA-SHIBA, M. KAYIKCIOGLU, K. LALIC, C.S.P. LAM, G. LATKOVSKIS, U. LAUFS, E. LIBEROPOULOS, J. LIN, V. MAHER, N. MAJANO, A.D. MARAIS, W. MARZ, E. MIRRAKHIMOV, A.R. MISEREZ, O. MITCHENKO, H.M. NAWAWI, B.G. NORDESTGAARD, G. PARAGH, Z. PETRULIONIENE, B. POJSKIC, A. POSTADZHIYAN, A. REDA, Z. REINER, W.E. SADOH, A. SAHEBKAR, A. SHEHAB, A.B. SHEK, M. STOLL, T.C. SU, T. SUBRAMANIAM, A.V. SUSEKOV, P. SYMEONIDES, M. TILNEY, B. TOMLINSON, T.H. TRUONG, A.D. TSELEPIS, A. TYBJAERG-HANSENB, A. VAZQUEZ-CARDENAS, M. VIIGIMAA, B. VOHNOUT, E. WIDEN, S. YAMASHITA, M. BANACH, D. GAITA, L.X. JIANG, L. NILSSON, L.E. SANTOS, H. SCHUNKERT, L. TOKGOZOGLU, J. CAR, A.L. CATAPANO a K.K. RAY. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). \textit{Atherosclerosis}. Clare: ELSEVIER SCI IRELAND LTD, 2018, roč.~277, OCT, s.~234-255. ISSN~0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2018.08.051.

Podrobný výpis o publikaci